A detailed history of Dimensional Fund Advisors LP transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 1,105,555 shares of VYGR stock, worth $8.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,105,555
Previous 932,231 18.59%
Holding current value
$8.74 Million
Previous $7.87 Million 30.81%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$7.15 - $10.84 $1.24 Million - $1.88 Million
173,324 Added 18.59%
1,105,555 $10.3 Million
Q4 2023

Feb 07, 2024

BUY
$6.28 - $8.81 $962,667 - $1.35 Million
153,291 Added 19.68%
932,231 $7.87 Million
Q3 2023

Nov 09, 2023

BUY
$7.55 - $11.25 $3.36 Million - $5.01 Million
445,545 Added 133.64%
778,940 $6.04 Million
Q2 2023

Aug 09, 2023

BUY
$6.94 - $13.99 $718,623 - $1.45 Million
103,548 Added 45.05%
333,395 $3.82 Million
Q1 2023

May 12, 2023

BUY
$6.0 - $10.78 $534,216 - $959,808
89,036 Added 63.23%
229,847 $1.77 Million
Q4 2022

Feb 09, 2023

BUY
$4.94 - $6.61 $231,132 - $309,268
46,788 Added 49.76%
140,811 $858,000
Q3 2022

Nov 10, 2022

SELL
$5.57 - $7.47 $91,364 - $122,530
-16,403 Reduced 14.85%
94,023 $556,000
Q2 2022

Aug 12, 2022

BUY
$4.82 - $10.09 $381,580 - $798,784
79,166 Added 253.25%
110,426 $652,000
Q4 2021

Feb 09, 2022

SELL
$2.47 - $5.55 $36,469 - $81,945
-14,765 Reduced 32.08%
31,260 $85,000
Q3 2021

Nov 12, 2021

SELL
$2.63 - $4.12 $16,555 - $25,935
-6,295 Reduced 12.03%
46,025 $121,000
Q2 2021

Aug 12, 2021

SELL
$3.94 - $5.44 $33,651 - $46,463
-8,541 Reduced 14.03%
52,320 $216,000
Q1 2021

May 14, 2021

BUY
$4.61 - $9.04 $59,694 - $117,058
12,949 Added 27.03%
60,861 $287,000
Q4 2020

Feb 25, 2021

BUY
$7.15 - $12.28 $342,570 - $588,359
47,912 New
47,912 $343,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $306M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.